S. Nishio, Beatriz Pardo, E. Hudson, Eliana Rulli, Y. Antill, Chulmin Lee, M. Rabaglio, Florian Heitz, Katharina Leitner, C-H. Lai, Sara Uggeri, Luis Manso, K. Harano, K. Allan, Yeh Chen Lee, G. Tognon, Stefania Canova, M. C. Petrella, A. Gadducci, N. Colombo
{"title":"523 阿特珠单抗联合卡铂和紫杉醇治疗晚期/复发性子宫内膜癌妇女的 III 期双盲随机安慰剂对照试验:AtTEnd/ENGOT-EN7 试验的亚洲队列","authors":"S. Nishio, Beatriz Pardo, E. Hudson, Eliana Rulli, Y. Antill, Chulmin Lee, M. Rabaglio, Florian Heitz, Katharina Leitner, C-H. Lai, Sara Uggeri, Luis Manso, K. Harano, K. Allan, Yeh Chen Lee, G. Tognon, Stefania Canova, M. C. Petrella, A. Gadducci, N. Colombo","doi":"10.1136/ijgc-2024-esgo.26","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517822,"journal":{"name":"Oral Sessions","volume":"33 33","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"523 Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of AtTEnd/ENGOT-EN7 trial\",\"authors\":\"S. Nishio, Beatriz Pardo, E. Hudson, Eliana Rulli, Y. Antill, Chulmin Lee, M. Rabaglio, Florian Heitz, Katharina Leitner, C-H. Lai, Sara Uggeri, Luis Manso, K. Harano, K. Allan, Yeh Chen Lee, G. Tognon, Stefania Canova, M. C. Petrella, A. Gadducci, N. Colombo\",\"doi\":\"10.1136/ijgc-2024-esgo.26\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":517822,\"journal\":{\"name\":\"Oral Sessions\",\"volume\":\"33 33\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral Sessions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2024-esgo.26\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Sessions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2024-esgo.26","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
523 Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of AtTEnd/ENGOT-EN7 trial